Quick Answer
Most patients begin noticing meaningful allergy symptom improvement after 6–12 months of allergy shots. Significant benefit is typically established after completing the buildup phase (4–6 months) and entering maintenance. Full disease-modifying effects that persist after stopping treatment require 3–5 years of continuous immunotherapy.
The Two Phases of Allergy Shot Treatment
Subcutaneous allergen immunotherapy (allergy shots, SCIT) proceeds in two distinct phases. The buildup phase begins with very small allergen doses given frequently — typically 1–2 times per week — and gradually increases the allergen concentration at each visit over approximately 4–6 months. Each injection is followed by a 20–30 minute observation period. The buildup phase trains the immune system to tolerate progressively higher allergen levels without reacting.
The maintenance phase begins once the patient reaches the target maintenance dose — the maximum therapeutic concentration that provides clinical benefit. Maintenance injections are given monthly (some protocols use every 6 weeks) and continue for 3–5 years. Symptoms typically continue to improve throughout the maintenance phase as immune tolerance deepens over time.
When Most Patients Notice Improvement
Approximately 80–90% of patients notice meaningful symptom reduction by the end of the first year of immunotherapy. Some patients with rapid immune responses may notice improvement within the first few months of the buildup phase. Others take 12–18 months to experience significant benefit. Environmental allergen patterns, allergen mix complexity, and individual immune response variability all influence the speed of benefit.
Studies comparing symptom scores in immunotherapy versus placebo groups show statistically significant divergence beginning at 3–6 months. The magnitude of benefit continues to increase through 2–3 years of treatment as the immune rebalancing deepens. Patients who discontinue too early (within the first year) often lose the benefit within 1–2 seasons.
How Long Do the Benefits Last After Stopping?
After completing a full 3–5 year course of allergen immunotherapy, approximately 70–80% of patients maintain significant symptom improvement for at least 3–7 years after stopping — sometimes permanently. This is the unique disease-modifying property of immunotherapy: it changes the underlying immune response rather than just suppressing symptoms while medication is taken.
Patients who complete shorter courses (1–2 years) are less likely to have sustained post-treatment benefit. Those who complete the full recommended course and respond well during treatment have the best prognosis for long-lasting benefit. Venom immunotherapy (for insect sting allergy) shows particularly durable protection — 95% of completers maintain protection for many years.
Who Benefits Most From Allergy Shots
Allergy shots are most effective for allergen-driven conditions with clearly identified IgE-mediated triggers. The best candidates include patients with moderate to severe allergic rhinitis (hay fever), allergic asthma with identified allergen triggers, insect venom allergy, and atopic dermatitis driven by specific environmental allergen sensitization. They are particularly valuable for patients who cannot tolerate or do not respond adequately to medications, or who prefer disease modification over long-term medication dependence.
Allergy shots are not effective for non-IgE-mediated conditions, food allergy (except through specialized protocols like OIT), irritant contact dermatitis, or allergic conditions without identified IgE-mediated triggers. Age is not a barrier — immunotherapy is effective in children and adults, including elderly patients.
Key Takeaways
- Buildup phase: 4–6 months of twice-weekly injections with escalating doses.
- Most patients notice meaningful improvement within 6–12 months.
- Maintenance: monthly shots for 3–5 years to achieve full disease-modifying effects.
- 70–80% of patients maintain sustained benefit for 3–7+ years after completing a full course.
- Venom immunotherapy offers 95% sustained anaphylaxis protection after course completion.
Related Guide
Allergy Treatment Hub →